Phase 3

Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab Deruxtecan as a New Standard

Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Topline Results from the Phase 3 SigVie-002 Study

Ifinatamab Deruxtecan (previously known as DS-7300a), a B7-H3-directed antibody-drug conjugate being developed by Daiichi Sankyo and Merck & Co. (known as MSD outside of the United States and Canada), could offer a First-in-Class option for patients diagnosed with extensive-stage small cell lung cancer (ES-SCLC) following platinum-based chemotherapy.

AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors

Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of Care in First-line PD-L1+ mTNBC

During the 44th J.P. Morgan Healthcare Conference, held January 12-15, 2026, in San Francisco (USA), Rakuten Medical and LOTTE Biologics signed a manufacturing agreement to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell killing.

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has approved an Investigational New Drug (IND) application for SKB105 (also known as CR-003 and PR-023), integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC) being developed by Sichuan Kelun-Biotech Biopharmaceutical, for the treatment of advanced solid tumors.

Izalontamab Brengitecan Receives U.S. FDA Breakthrough Therapy Designation Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Compelling evidence presented at the European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025, in Berlin, Germany, has shown that a new generation of antibody-drug conjugates (ADCs) can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.

Datopotamab deruxtecan (datopotamab deruxtecan-dlnk in the U.S. only; Datroway®; Daiichi Sankyo and AstraZeneca; see ADC Drug Map) has been approved by the U.S. Food and Drug Administration (FDA)